Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/01/2003US20030083323 Oral use of dehydroepiandrosterone and some of its derivatives as pigmentation regulators
05/01/2003US20030083322 For androgenic alopecia or hirsutism; physiologically tolerated film-forming agent and solvent, a plasticizer and compound such as 4-(5-methyl-2,4-dioxo-5-trifluoromethyl)-oxazolidin-3-yl)-2 -(trifluoromethyl)-benzonitrile
05/01/2003US20030083321 Composition and method for minimizing or avoiding adverse effects of vesicants
05/01/2003US20030083320 22-oxa-1a,25-dihydroxyvitamin D3 as an active ingredient; inhibiting mesangial cell proliferation or mesangial matrix production without causing hypercalcemia; treating diabetic nephropathy
05/01/2003US20030083319 For treating osteoporosis, secondary hyperparathyroidism, cancer and autoimmune diseases without inducing hypercalciuria, hypercalcemia, or nephrotoxicity
05/01/2003US20030083318 Therapy for neurodegenerative diseases
05/01/2003US20030083316 Dioxolane nucleosides and nucleoside analogues such as troxacitabine together with chemotherapeutic agents other than doxorubicin such as cytarabine, gemcitabine and idarubicin; synergistic mixture; treating leukemia, cancer
05/01/2003US20030083315 Benzimidazole derivatives for treating an inflammatory disease, an allergy disease, a respiratory disease, a cardiovascular disorder or a bone disorder
05/01/2003US20030083313 Means of tumor therapy
05/01/2003US20030083310 Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of a parenterally administrable pharmaceutical composition
05/01/2003US20030083309 A mixture comprising a drug complexed with a water soluble polydextrose and a polymer matrix; time-release agents
05/01/2003US20030083308 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes and DNA viruses
05/01/2003US20030083307 Anti-HCV nucleoside derivatives
05/01/2003US20030083300 Antisense modulation of cellular inhibitor of Apoptosis-2 expression
05/01/2003US20030083298 Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis or growth of DMS
05/01/2003US20030083297 Antisense modulation of daxx expression
05/01/2003US20030083296 Antisense modulation of caspase 8 expression
05/01/2003US20030083295 An oligonucleotides are hybridizable with nucleic acids to inhibit the gene expression of enzyme
05/01/2003US20030083294 Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving
05/01/2003US20030083286 Comprises penetration enhancer (fatty acid); drug delivery; increases bioavailability of oligonucleotides
05/01/2003US20030083280 Oligonucleotides which hybridize with nucleic acids which encode said protein; gene therapy; genetic engineering; for treatment of angina and myocardial infarction
05/01/2003US20030083275 Antisense oligodeoxynucleotides regulating expression of tnf alpha
05/01/2003US20030083272 Sense mrna therapy
05/01/2003US20030083271 Such as 12-(6-deoxy-6-fluoro-D-galactopyranosyl)-3,9-difluoro-12,13-dihydro-5H -indolo(2,3-a)pyrrolo(3,4-c)carbazole -5,7(6H)-dione for inhibiting proliferation of tumor cells
05/01/2003US20030083269 Nictoinamide adenine dinucleotide (NAD); microbiocides; antiseptics; plant safening agents; antibiotic resistance; agriculture; food treatment
05/01/2003US20030083268 Isoquinoline compounds having antiinfective activity
05/01/2003US20030083267 For inhibiting the binding of ligands to antigens; prophylaxis and treatment of inflammatory and autoimmune diseases such as asthma, arthritis, psoriasis, transplantation rejection, multiple sclerosis, diabetes, and inflammatory bowel disease
05/01/2003US20030083266 Administering N-acetyl cysteine ethyl ester for prophylaxis of stroke and trauma
05/01/2003US20030083261 Anticancer agents
05/01/2003US20030083259 Use of a peptide
05/01/2003US20030083257 Spliceable nucleotide sequence inserted into the wild-type factor viii cDNA at the original position of an intron of the genomic factor viii DNA; gene therapy; treatment of hemophilia
05/01/2003US20030083256 Compositions and methods for enhancing drug delivery across and into epithelial tissues
05/01/2003US20030083254 Heparanase-like proteins and nucleotides that encode them
05/01/2003US20030083250 Increasing the supply of red blood cells
05/01/2003US20030083242 Methods and compositions for treating or preventing peripheral neuropathies
05/01/2003US20030083233 Aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders; oxygen-carrying component consists of hemoglobin-based oxygen carrier, non-oxygen carrying plasma expander consists of diluent; blood substitutes
05/01/2003US20030083231 Used of androstane derivatives in treatment of conditions such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy
05/01/2003US20030083228 Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction
05/01/2003US20030083227 Novel combination therapy to treat glaucoma
05/01/2003US20030083226 Composition having reverse transcriptase inhibitor activity
05/01/2003US20030082805 Methods for use of mpl ligands with primitive human stem cells
05/01/2003US20030082802 Preparing culture of nervous system tissues; prepare nutrient broth containing agonist, inoculate with nervous system stem cells, propagate and recover cells
05/01/2003US20030082793 Method for preparation of physiologically active water-base extract and method for potentiating the activity thereof
05/01/2003US20030082780 Nucleotide sequences coding polypeptide for use in the treatment of infections, pneumonia, toxic shock, brain and rheumatic diseases
05/01/2003US20030082748 Nucleotide sequences coding polypeptides for use in the treatment of leukemia, tumors, psoriasis, chronic infections, autoimmune and fibrotic disorders; wound healing agents
05/01/2003US20030082725 DNA encoding a novel human inhibitor-of-apoptosis protein
05/01/2003US20030082722 Method for amplifying expression from a cell specific promoter
05/01/2003US20030082674 Genetically engineered receptor protein for use in the treatment of respiratory system disorders
05/01/2003US20030082672 Dna encoding galanin galr2 receptors and uses thereof
05/01/2003US20030082666 Therapeutic treatment for autoimmune dseases; obtain hyperacetylation agent, administer to mammal, monitor adjustment in acetylation, amplified acetylation indicates treatment for autoimmune diseases
05/01/2003US20030082646 Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
05/01/2003US20030082631 Detecting modulator of peroxisome proliferator-activated receptor; obtain sample contain proxisome receptor, incubate with test agent, monitor sample for adjustment in receptor activity
05/01/2003US20030082620 Novel human genes and gene expression products: II
05/01/2003US20030082612 Detection of mutant leptin receptor; obtain cells, extract nucleotide sequences, incubate with an oligonucleotide probe, detect hybridization, presence of hybridization, indicates defective receptor
05/01/2003US20030082610 Evaluation of pharpharmacological and non-pharmacological therapies for weight reduction; obtain nucleotide sequences coding human g-protein, mutate and express cells, monitor adjustment in gene expression and weight
05/01/2003US20030082609 Nuceotide sequences coding polypeptide for use in humans therapeutics and diagnostics
05/01/2003US20030082554 Nucleotide sequences coding polypeptide for use in the treatment of immunlological, thyroid, metabolic, bone and pancreatic disorders
05/01/2003US20030082519 Cellular kinases involved in Cytomegalovirus infection and their inhibition
05/01/2003US20030082510 Treatment for viral or bacterial infections of blood; obtain blood sample, incubate with test compound, expose to light, evaluate sample for presence active pathogen
05/01/2003US20030082286 Low calorie; sugar replacement
05/01/2003US20030082271 Chewing gum containing controlled release acyclic carboxamides
05/01/2003US20030082249 Compositions containing capsaicin and its derivatives, and their use in treating mucositis
05/01/2003US20030082247 Obesity inhibitory materials
05/01/2003US20030082239 Antifungal compositions with improved bioavailability
05/01/2003US20030082238 Matrices for drug delivery and methods for making and using the same
05/01/2003US20030082234 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
05/01/2003US20030082230 Chronotherapeutic dosage forms and methods of treatment using chronotherapy
05/01/2003US20030082229 Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
05/01/2003US20030082227 Drug delivery; multilayer reservoir
05/01/2003US20030082226 Non-steroidal antiinflammatory drug formulations for topical application to the skin
05/01/2003US20030082225 Sterile, breathable patch for treating wound pain
05/01/2003US20030082224 Antitumor, anticancer agents
05/01/2003US20030082223 Mixture contains flow control agent and thickener
05/01/2003US20030082214 Oil in water emulsion containing antidepressant, anesthetics
05/01/2003US20030082212 Desensitization therapy; reducing allergens sensitivity; administering prednison and antihistamines
05/01/2003US20030082207 Method of using HIV protease inhibiting compounds
05/01/2003US20030082203 Immune functions
05/01/2003US20030082183 Methods and compositions for treatment of ocular neovascularization and neural injury
05/01/2003US20030082176 Therapy for metabolism disorders
05/01/2003US20030082172 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
05/01/2003US20030082169 System and method for the pretreatment of the endplates of an intervertebral disc
05/01/2003US20030082168 Prevent carbohydrate absorption; moderate metabolism; mixture of wheat amylase, plant extracts, linoleic acid and green tea
05/01/2003US20030082155 Antidiabetic agents; cell differentiation of stem cells
05/01/2003US20030082151 Extension of the expression of transgenic proteins by immunomodulation
05/01/2003US20030082150 Recombinant adenoviral vectors for human tumour gene therapy
05/01/2003US20030082141 COX-2 function and wound healing
05/01/2003US20030082140 Increasing the amount of the cell differentiation associated protein, MDA-7 and decreasing RAS gene activity by administering a viral vector comprising an MDA-7 gene and an antisense ras oligonucleotide; treating pancreatic cancer
05/01/2003US20030082133 Biocide treating anthrax; highly stable and safe for exposure to human skin; antibiological warfare agents, for surface coatings
05/01/2003US20030082120 Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family
05/01/2003US20030082109 Chewable or edible substitutes for smoking for enabling gradual withdrawl from dependency or addiction
05/01/2003US20030082108 Inhibitors of enzymes that metabolize arachidonic acid; peroxisome proliferator-activated receptors (ppar)
05/01/2003US20030082107 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
05/01/2003US20030082105 Selectively targeted fluorescent, radiolabeled, or fluorescent and radiolabeled compositions
05/01/2003US20030079311 Suspension bushing, motor vehicle and a suspension cross-member for a motor vehicle
05/01/2003CA2764642A1 Taste masking spill-resistant formulation
05/01/2003CA2739611A1 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
05/01/2003CA2498591A1 Immunotherapy for reversing immune suppression
05/01/2003CA2466813A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003CA2466806A1 Method of resolving amlodipine racemate
05/01/2003CA2464981A1 Quinoline compound
1 ... 5485 5486 5487 5488 5489 5490 5491 5492 5493 5494 5495 5496 5497 5498 5499 5500 5501 5502 5503 5504 5505 ... 7860